HR070803

· Jiangsu HengRui Medicine Co., Ltd.

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for HR070803, covering 2022-09-06 to 2025-11-18. Get the full timeline:

Most recent: Clinical Trial Update: A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer [Phase 2, Phase 3]

See pricing